Compliance Testing and Assessment of CMR Substances in Medical Devices - Medical Devices

1. CMR Substances

CMR substances are a collective term for three categories of hazardous chemicals: Carcinogens, Mutagens, and Reproductive toxicants. These substances pose severe challenges to medical device manufacturers, mainly in four aspects:

Hidden risks: The hazards of CMR substances usually appear only after long-term exposure and are difficult to detect promptly through routine post-market surveillance systems.
Complex identification: Determining whether a substance is classified as CMR requires professional toxicological knowledge and data support and is not self-evident.
Strict regulations: Regulations such as the EU MDR set stringent standards, imposing higher compliance responsibilities on manufacturers.
Difficult burden of proof: Proving to regulatory authorities that CMR substances are “not present” or “adequately controlled” in a product requires establishing a complete evidence chain.

2. Identification and Classification Methods for CMR Substances

Manufacturers must fully understand the substances contained in and potentially released from medical device materials and accurately determine their CMR properties. Identification mainly relies on the following approaches:

Authoritative database queries: Toxicological databases such as the ECHA Chemical Database (EU) and the GESTIS Database (Germany) compile experimental data on substances and serve as important references for judging CMR characteristics. The QSAR Toolbox can be used to improve cross-database query efficiency.

Regulatory list verification: Annex VI Table 3 of the EU CLP Regulation (Regulation (EC) No 1272/2008) is the official CMR substance list with the highest authority. Other reference lists include the European Commission’s overview of CMR substances, Germany’s IFA CMR list, IARC classifications, etc.

Important Note: Different databases may provide conflicting conclusions based on different research data. In case of unclear classification, consultation with a toxicology expert is recommended.

3. Source Analysis of CMR Substances

CMR substances can enter medical devices through three main pathways:

1. Inherent in raw materials: Present directly as components in purchased raw materials, such as plastic pellets, metal alloys, and coating materials.

2. Process residues: Residues of chemicals used in production, such as cleaning agents, mold release agents, adhesives, etc.

3. Processing-generated substances: New substances formed by chemical changes in materials during processing such as high-temperature sterilization, welding, and curing reactions.

4. Core Regulatory Requirements

EU MDR Requirements

Concentration limit: CMR substances in materials of medical devices used for administering or storing medicinal products, body fluids, and invasive devices shall not exceed 0.1% by weight.
Exception justification: If exceeding the limit, a scientific report must be provided, including potential exposure analysis, alternative assessment, justification for unavailability of alternatives, and risk considerations for vulnerable populations.

ISO Standard Requirements

ISO 10993-1: Genotoxicity, carcinogenicity, and reproductive toxicity must be evaluated.
ISO 10993-17: Provides a risk assessment approach for carcinogenic substances.

Other Regulations

Compliance with REACH, CLP, and relevant national regulations is also required. Risk labeling may be necessary on product labels and instructions for use where applicable.

5. Systematic Assessment Process

CMR substance testing and assessment shall follow a three-step approach:

Step 1: Document Review and Source Screening

Systematically review Safety Data Sheets (SDS/MSDS) of all raw materials and process chemicals, complete material suitability review, and identify potential risks from the supply chain source.

Step 2: Finished Product Material Testing and Analysis

Conduct testing and analysis on the final medical device to accurately determine the presence and concentration of CMR substances.

Step 3: Risk Assessment

Perform professional risk assessment based on test data, compare results with safety limits, and quantify potential exposure risks.

The assessment forms a closed loop:

If the risk is acceptable, compliance is achieved.
If the risk is unacceptable, specific migration testing is initiated and reassessment is performed.

6. Recommended Actions for Enterprises

Source control strategy: Prioritize raw materials free of CMR substances and ensure concentrations are below the 0.1% limit.
Early testing principle: Conduct chemical characterization during the design phase to allow time for material substitution and design optimization, avoiding high rework costs at later stages.
Compliance with standard procedures: Strictly follow the ISO 10993 series standards, ensure assessments include complete chemical characterization, and establish a systematic evidence chain.
Professional capability assurance: Ensure the team has toxicological expertise to accurately assess exposure levels and risks to vulnerable populations.

CMR substance management is a critical component of material compliance for medical devices. Companies should adopt a "prevention-first, systematic assessment" approach—avoiding the use of CMR substances at the design stage whenever possible, providing compliance evidence through systematic testing, and ensuring that toxicological risk assessments are conducted by qualified experts. This process not only fulfills regulatory requirements but also significantly enhances product safety and market competitiveness.

CIRS Testing offers a one-stop service for CMR substance testing and evaluation, helping companies accelerate time-to-market for their products.